Welcome to our dedicated page for Anteris Technologies Global SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anteris Technologies Global Corp. filings document the regulatory record of a structural heart medical device issuer developing the DurAVR® Transcatheter Heart Valve for aortic stenosis. Its reports and material-event filings cover operating and financial results, Form 10-K disclosures, clinical and regulatory activity tied to the PARADIGM trial, research and development spending, risk factors and management discussion of liquidity and operations.
The company’s SEC filings also describe material agreements, facility leases, strategic investment and public offering activity, common-stock capital structure, registration statements, equity incentive awards, director and officer governance matters, subsidiary arrangements and disclosures furnished for ASX reporting. These documents connect AVR’s device-development program with financing, governance and public-company reporting obligations.
Anteris Technologies Global Corp. disclosed that Sio Capital Management, LLC beneficially owned 2,934,027 shares of the issuer's common stock, representing 8.14% of the class based on 36,062,087 shares outstanding. Sio reports no sole voting or dispositive power and instead holds these shares with shared voting and shared dispositive power. The filing describes Sio as a Delaware-registered investment adviser acting for affiliated funds that directly hold the shares, and notes that Sio GP, LLC and Michael Castor may be deemed to have control but expressly disclaim beneficial ownership.
Anteris Technologies Global Corp. (AVR) reported continued development-stage results as it scales toward a pivotal US trial. Net sales were $0.6 million for Q2 2025 and $1.17 million for the six months, while operating investment drove a loss after tax of $42.99 million for the six months ended June 30, 2025. Cash declined to $28.4 million from $70.5 million at year-end 2024 as operating cash outflows totaled $41.0 million in H1 2025.
The company increased R&D spending to $32.8 million for H1 2025 to scale manufacturing and prepare the PARADIGM randomized pivotal trial; 79 sites are qualified for that study. Anteris completed a U.S. IPO and received net proceeds of $80.0 million (including the over-allotment), but management discloses substantial doubt about the company’s ability to continue as a going concern without additional capital.
Anteris Technologies Global Corp. (Nasdaq AVR) has filed a PRE 14A calling a fully virtual special meeting for 4 Sep 2025.
Shareholders will vote on: (1) ASX’s three-year waiver of Listing Rule 7.1, allowing equity issuances above the current 15 % cap without prior ASX shareholder approval, and (2) authority to adjourn the meeting to gather more proxies if Proposal 1 lacks support.
The board argues the waiver aligns AVR with U.S. peers and provides funding flexibility for the DurAVR THV program, while Nasdaq’s 20 % and change-of-control rules will still govern large deals.
Proposal 1 needs 75 % of votes cast; Proposal 2 needs a simple majority. Illustrative scenarios show potential shareholder dilution from 8 % up to 73 %, depending on deal size and price. Record date is 11 Aug 2025; CDI holders must instruct CDN to vote on their behalf.
The board unanimously recommends voting FOR both proposals.